maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon GLP-1 Receptor Agonists: The New

There are several reasons your doctor might recommend you avoid GLP-1s

BozzettoLAnnuzziGRagucciMDi DonatoODella PepaGDella CorteGet al

Curr Opin Obstet Gynecol 29(3):180187 Marshall NE, Abrams B, Barbour LA et al (2022) The importance of nutrition in pregnancy and lactation: lifelong consequences

Dosing began at 0.5 nmol/kg/day and was increased in approximately one-third-log increments (10 n/3 ) until the MTD was established

Most safety data focuses on gastrointestinal and endocrine effects, leaving a gap in understanding how these drugs may affect the skin

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity